Over the last 150 years, the U.S. Food and Drug Administration (FDA) has evolved from a small division of the U.S. Patent
R egulation of the development, production, marketing, and sales of medical pharmaceuticals and devices entails paradoxical goals.
It must ensure that new and effective medical treatments reach the public rapidly while simultaneously providing protection from ineffective or even unsafe therapies and from predatory marketing practices that tout unproven remedies to vulnerable patients.
In the United States, these regulatory functions fall to the U.S. Food and Drug Administration (FDA). to approximately 17 per year after 1965 (2, 4) . It is unclear whether FDA regulations were entirely responsible for the deceleration, because foreign countries also experienced a lag (2, 5, 6) , but it was nevertheless obvious that new drugs and devices were often reaching the market in other countries months to years before achieving FDA approval in the United States (2) . Modern regulations allowing for expanded access and accelerated approval for drugs to treat life-threatening conditions have their origins in the public outcry over delays in access to acquired immune deficiency syndrome treatments in the 1980s (7) . But, movements to "deregulate" drug development by loosening FDA regulations have been weakened by the occurrence of major safety incidents, such as with benoxaprofen in 1982 (2) . The nonsteroidal anti-inflammatory agent, marketed under the brand name Oraflex, was released to the public but then withdrawn when patient deaths were reported in the United Kingdom (8, 9) . Thus the drug/device development environment in the United States involves a constant balance between accelerating pressures to expedite effective therapies to the public, and the mission to minimize major adverse events (10) .
Today, the path from initial demonstration that a molecule may have therapeutic potential to the production of an approved drug involves pre-clinical testing, complex clinical trials in humans, and posttrial regulatory approval by the FDA. For drugs, this process can take 10 to 15 years and cost millions of dollars (11) . A recent analysis suggests that the actual cost of taking a new drug from concept to market as of 2014 is now above $1.3 billion (12 (14, 15) .
The pathways for approval of medical devices are shorter and generally less costly when compared with the regulatory process for drugs. Although the drug development takes on average 12 years from concept to market, the same process for medical devices averages 3 to 7 years (16).
For researchers involved in the clinical development and testing of putative drugs and devices, the process of FDA approval can be daunting and difficult to navigate. This first part of a 2-part series is intended to provide an overview of the steps in bringing a drug through the process of clinical trials and FDA approval. The second part of this series will discuss the process of obtaining approval to study devices, which have their own unique pathway.
PART 1: FDA APPROVAL OF NEW DRUGS
WHAT IS A DRUG? Not every substance taken by patients "for their health" is considered a drug by the FDA ( Table 1) . The FDA defines herbal products, vitamins, and other complementary medical therapies as "dietary supplements" (17) . As such, they are 
Drugs, Devices, and the FDA a drug, followed by pre-clinical development involving in vitro and in vivo studies and drug prototype design ( All drugs will go through review by a committee, or 
P a t h w a y 1 : t h e i n v e s t i g a t o r I N D . An investigator
IND is submitted by a physician, sometimes on behalf of an institution or "sponsor" such as a pharmaceutical company ( Table 3) . The investigator will both initiate and conduct the investigation and direct the dispensing and administration of the drug. Conduct pre-clinical studies: in vivo and in vitro studies to determine the efficacy and safety of proposed drugs in animal models, including carcinogenicity, mutagenicity, and teratogenicity
On the basis of results from pre-clinical studies, begin to design proposed clinical trials in humans to study safety and efficacy
Begin initial work to determine pharmaceutical formulation and outline potential manufacturing processes
Evaluate the formulated drug's purity and stability through the manufacturing process Step 1 Contact the appropriate division of the FDA and set up a Pre-IND Consultation Program; check FDA guidance documents to be sure the new drug does not qualify for an exemption from IND application (uncommon, but can occur with some generic drugs and radiological products)
Step 2 Submit the application (original and 2 copies) to: Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
5901-B Ammendale Road
Beltsville, Maryland 20705-1266
Step 3 If the FDA does not raise an objection within 30 days of submission of the application, the investigator may proceed
Step Van Norman
Drugs, Devices, and the FDA A P R I L 2 0 Table 4 . This contact information is current as of March 4, 2016, but may be updated and can be found at the FDA web site (26) . In emergency cases, the FDA will often authorize use of the agent in advance of a full IND, which must then be completed in a timely fashion. The process and timeline for EIND applications are summarized in Table 5 .
P a t h w a y 3 : t h e t r e a t m e n t I N D . Table 7 , and major steps in the clinical trials phase and IND review are summarized in Table 8 . Table 3 . As soon as possible, but no later than 7 days after occurrence Mandatory report of life-threatening or fatal occurrences.
As soon as possible, but no later than 15 days after occurrence Report serious or unexpected suspected adverse reactions.
Any time during the IND application life Submit amendments to the EIND applications if there are any changes to information sent with the initial EIND application.
Following completion of EIND treatment Send FDA written summary of the results of the investigational treatment.
After 1 year (if EIND application is still active) and within 60 days of the anniversary of the FDA's authorization date
Send EIND application annual report to the appropriate review division of Center for Drug Evaluation and Research.
EIND ¼ emergency investigational new drug; other abbreviations as in Table 3 . Safety determines the highest tolerable dose or optimal dose needed to achieve the desired clinical benefit and potential adverse effects in that exposure range.
Efficacy determines whether a drug has a positive clinical benefit over placebo or other intervention. Efficacy tests involve "ideal," that is, strictly controlled conditions.
Effectiveness describes a drug's clinical benefits in a "real world" situation, for example, where patients may have comorbid conditions or other medications that interact with the drug, and where drug administration may not following strict study guidelines.
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Drugs, Devices, and the FDA A P R I L 2 0 1 6 : 1 7 0 -9 Submission of NDA NDA asks the FDA for marketing approval of the drug 60-day waiting period FDA has 60 days to determine if they will file the application and start the review process FDA review team assigned to the drug FDA reviews information that goes into a drug's professional labeling FDA inspects facilities where the drug will be manufactured FDA approval Drug is approved for marketing OR response letter from FDA outlining further actions NDA ¼ new drug application; other abbreviations as in Table 3 . Abbreviations as in Table 3 .
Drugs, Devices, and the FDA of the drug. The number of subjects is still low, usually between 20 and 80 (35) , and subjects are generally healthy because clinical effectiveness is not an endpoint of the trial.
Single-dose studies are the usual starting place of Phase I trials: the subject is given a single dose of drug no greater than one-tenth the highest dose associated with no adverse effects in the most sensitive animal safety studies (34). Many researchers now believe that single-dose toxicity trials should not be carried out simultaneously in multiple subjectsmeaning that the drug should be tested in a single subject and enough time be allowed between subjects such that a severe reaction in any subject will lead to termination of the study before other subjects are exposed (25, 36) . A recent, disastrous clinical trial serves to underscore this concern; in the initial Phase Van Norman FDA review occurs within 180 days of receipt of a complete application (38) . An accelerated process is available for generic drugs, products that provide "meaningful therapeutic benefit" over existing drugs, those that concern serious or life-threatening conditions, or those that address a previously unmet medical need. If the application is found to have deficiencies, the clock stops on review while the manufacturer is given an opportunity to respond to the deficiencies or withdraw the application. If approval of the NDA is denied, the FDA sends a complete response letter describing specific deficiencies and recommending ways for the applicant to make the application viable. Unsuccessful applicants may request a hearing.
Upon review and approval of the NDA, the manufacturer is free to manufacture and market the drug. A summary of the timeline, costs, and overall probability of success for the drug development process can be found in Figure 1 (12,41) . The highest failure rates occurs in Phase II testing, which is the first stage in which doses of drug in humans are escalated to reach levels expected to be clinically active (i.e., the first doses at which efficacy may fail and less common side effects appear). Cumulative probability of a drug reaching U.S. Food and Drug Administration approval declines with each stage. The overall probability of a drug passing all stages is approximately 11% as of 2014 (12) .
SUMMARY
The United States has arguably the most stringent Van Norman Drugs, Devices, and the FDA A P R I L 2 0 1 6 : 1 7 0 -9
